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Background: Platelet function testing is a valid tool to investigate the clinical response
to antiplatelet therapy in different clinical settings; in particular, it might supply helpful
information in patients with cerebrovascular disease. Oral antiplatelet treatment, such
as Aspirin (ASA) and Clopidogrel, is the gold standard in secondary stroke prevention
of non-cardiogenic ischemic stroke; conversely, its application as a primary prevention
therapy is not routinely recommended in patients with vascular risk factors. Multiple
electrode platelet aggregometry (MEA) impedance aggregometer is a validated device
to test platelet inhibition induced by ASA or Clopidogrel.
Case Report: We report the case of a 78-year-old patient without relevant clinical
history, taking ASA as primary prevention strategy, who was admitted for sudden onset
of dysarthria and left facial hyposthenia during physical effort. Brain CT revealed two
small subcortical bilateral spontaneous intracranial hemorrhages. Platelet aggregometry
with MEA performed upon admission revealed a very strong platelet inhibition induced
by ASA (result of the ASPI Test was 5U, consistent with an ultra-responsiveness to ASA,
and the cutoff value of correct responsiveness is <40U). MRI at longitudinal follow-up
revealed the presence of two small cavernous angioma underlying hemorrhagic spots.
Conclusion: The evaluation of platelet reactivity in stroke patients undergoing
antiplatelet therapies, not commonly performed in clinical practice, could be useful to
optimize prevention strategies; the verification of the biological effectiveness of ASA or
Clopidogrel could be a valid tool in the definition of each patient’s risk profile, particularly in
patients with cerebrovascular disease known to be at increased risk for both hemorrhagic
and thrombotic complications.
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BACKGROUND
International leading guidelines strongly recommended
antiplatelet therapy in secondary prevention of non-cardiogenic
strokes, as it is associated with an estimated reduction of relative
risk of stroke or death on average by about 22% (1, 2). Conversely,
the use of pharmacological strategy for primary cardiovascular
prophylaxis, including stroke prevention, is still a debated topic
(3). It is mandatory to improve the control of modifiable risk
factors, such as hypertension and diabetes, but antiplatelet agents
have no clear indications (3). Recently, the ACC/AHA guideline
suggests to address primary prevention with low-dose Aspirin
daily treatment to selected patients between 40 and 79 years of
age, who are at higher risk for ischemic vascular event, but not at
increased bleeding risk (4).
Therefore, the use of Aspirin might be reasonable only for
people whose 10-year vascular risk is notable (at least higher
than 10%) for the benefits to outweigh the risks associated
with treatment. In particular, the association of diabetes mellitus
with other high-risk conditions has been considered for primary
prevention strategies (1, 3, 4).
Platelet function testing is a valid tool to investigate
the clinical response to antiplatelet therapy in different
clinical settings; several clinical and biological mechanisms for
antiplatelet “resistance” or, conversely, “ultra-responsiveness”
have been supposed (incongruent dose, poor compliance, genetic
polymorphisms, baseline hyperactivity, and/or accelerated
platelet turnover) (5–7). Thus, the possibility of testing the
biological effectiveness of antiplatelet medications in vascular
patients could be potentially useful for promptly detecting
any relevant clinical problems, including safety in ultra-
responder patients (8). However, the implementation of platelet
function testing in routine clinical practice is not widely
supported, mainly due to a lack of consensus on the effective
improvement of clinical outcome with tailored therapy; other
studies conversely debated the usefulness of platelet function
monitoring, particularly in terms of reliability of results between
different tests available (9, 10).
Within impedance aggregometers, the device “Multiple
Electrode Platelet Aggregometry” (MEA, Multiplate Analyzer R©,
Roche Diagnostics International Ltd., CH-6343 Rotkreuz,
Switzerland) (11, 12) showed correlation with the estimates
of the antiplatelet effect of Clopidogrel and ASA obtained by
other methods (13). Platelet aggregometry is a function test
based on the stimulation of platelet–platelet aggregation with
various agonists [adenosine diphosphate (ADP), arachidonic
acid (ASPI), and thrombin receptor-activating peptide (TRAP)]
and can be used to monitor the effects of antiplatelet agents,
classified into three groups regarding their mechanism of
action (thromboxane inhibitors—Aspirin, ASA, ADP receptor
antagonists—Clopidogrel, and glycoprotein IIb/IIIa inhibitors).
A comprehensive overview of platelet activation pathways
is summarized in Figure 1A. According to the principles
of impedance aggregometry, Multiplate Analyzer R© assessed
residual platelet function in whole blood of patients undergoing
antiplatelet therapy; every test is performed in a single-use
test cell, which incorporates two independent impedance metal
sensors. After the addition of specific agonists (ADP, ASPI, and
TRAP), the platelet–platelet aggregation is induced and real-time
recording starts. The ADP Test reagent contains ADP, which
triggers platelet activation via different ADP receptors, the most
important of which is blocked by Clopidogrel (14). The ASPI Test
reagent contains arachidonic acid, whose activation pathway is
blocked by ASA (15); TRAP aggregation test is used to obtain
a platelet aggregation measure relatively independent of others,
supporting the proper sample preparation. Once activation
of platelet aggregation starts on metal sensors, the electrical
resistance increases; the resistance change is transformed to
arbitrary aggregation units (AUs) and plotted against time.
The area under the aggregation curve (AUC) quantifies the
aggregation response, expressed in units (U; 1U corresponds to
10 AU∗min) (Figure 1B). Cutoff value of the ASPI Test indicating
correct responsiveness to ASA is <40U (16), while values under
30U indicate strong enzymatic inhibition and higher risk of
bleeding (17).
CASE PRESENTATION
A 78-year-old man without relevant clinical history was admitted
in the Stroke Unit for sudden onset of slurred speech and left oral
rhyme deviation during physical effort, without headache and/or
limb weakness. Patient’s past medical history reported bilateral
neurosensory hypoacusis, previous cataract surgery, and carpal
tunnel syndrome surgically treated. Pharmacological anamnesis
revealed daily treatment with Aspirin 100mg as a vascular
primary prevention strategy, started 3 months before.
Neurological examination showed paralysis of right VII
cranial nerve, right deviation of protruded tongue, and mild
dysarthria (NIH stroke scale 2/42). Brain CT revealed multiple
chronic lacunar infarctions of basal ganglia bilaterally, and
two acute small intraparenchymal hemorrhages, within post-
rolandic subcortical region on the right side (Figure 2A) and
pre-rolandic subcortical region on the left side (Figure 2B); CT
angiography showed mild carotid and vertebral atherosclerosis,
and no vascular malformation (Figure 2C).
Aspirin therapy was immediately discontinued. Intensive
monitoring in the Stroke Unit and cardiac ultrasound
revealed an unknown arterial hypertension, with a chronic
hypertensive cardiopathy. Target therapy with ACE inhibitors
(Enalapril 20mg once daily) was started, with blood pressure
normalization. Multiplate R© platelet function analysis performed
upon admission revealed a very strong platelet inhibition
induced by ASA; the area under the aggregation curve (AUC) on
the ASPI Test was 5U, consistent with an ultra-responsiveness to
ASA, with normal platelet aggregation induced by other agonists
on the ADP Test and TRAP Test (Figure 3).
Neurological examination of patients at discharge was
completely normalized. Due to the “atypical” locations of
intraparenchymal hematomas, we performed a brain MRI at
longitudinal follow-up in order to exclude non-hypertensive
causes of bleeding. Gradient-echo T2∗-weighted sequences
revealed two small roundish lesions, in the anatomical site
of bilateral subcortical hematomas, with minute central
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FIGURE 1 | (A) Schematic overview of platelet activation/inhibition pathways and impedance aggregometry tests (ADP Test, ASPI Test, and TRAP Test). (B) Graphic
presentation of platelet–platelet aggregation induced during each test; platelet responsiveness is quantified by the area under the curve (AUC*min). Modified from
Roche Diagnostics International.
nucleus of methemoglobin and dark hemosiderin rim, and
without surrounding edema, consistent with cavernous venous
malformations (Figure 4A). Multiple similar but smaller
cavernous angiomas were detected throughout subcortical white
matter on both sides, particularly in temporal and occipital lobes,
and in the area of basal ganglia (Figures 4B,C). On differential
diagnosis, T2 and FLAIR sequences excluded findings suggestive
of other conditions, as possible cerebral amyloid angiopathy;
no evidence of significant subcortical leukoencephalopathy was
detected besides lacunar microinfarcts in the region of basal
ganglia bilaterally, and no signs consistent with superficial
siderosis were detected.
DISCUSSION
We presented a case of a previous healthy patient,
admitted for intracerebral atypical hemorrhages, taking no
medications except ASA in primary prevention. Diagnostic
workup revealed a condition of unrecognized arterial
hypertension, and the presence of multiple intracerebral
cavernous venous malformations, some of which with acute
bleeding. Symptomatic hemorrhagic complication occurs
as a clinical manifestation of cavernous angioma in 25%
of cases (18), but the annual average rate of bleeding is
reported to be lower in patients without history of prior
hemorrhage (19). However, rupture rate rises in patients
with associated condition at risk of bleeding, such as
hypertension. Many studies suggest the likely safety of
antiplatelet medications in patients with cerebral cavernous
malformations (19), but outside of randomized controlled
protocols (20).
The role of antiplatelet agents for the primary prevention of
cardiovascular disease, including stroke, is still widely debated,
due to the delicate balance between efficacy and safety in
patients without established previous vascular events. Several
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FIGURE 2 | Brain CT scans showing bilateral intraparenchymal hyperdense lesions (red arrows): a small hemorrhagic spot in the post-rolandic area on the right (A)
and a greater hematoma in the left pre-rolandic area (B). (C) CTA with no evidence of vascular malformations.
FIGURE 3 | Platelet function testing performed upon admission during Aspirin therapy. Marked reduction of AUC on ASPI Test, 5U, expressing a strong platelet
inhibition induced by ASA (ultra-responder patient). Expected values in healthy individuals are in brackets.
randomized clinical trials showed that Aspirin is effective in the
reduction of recurrence risk, with a tolerable increase of bleeding
complications; thus, international practice guidelines strongly
recommended ASA in secondary prevention of vascular diseases,
as ischemic stroke or myocardial infarction (1). Regarding
primary prevention, diverging results have contributed to
unclear indications about antiplatelet therapy, which is not
routinely recommended, primarily due to safety (4). Therefore,
in clinical practice, ASA treatment should be tailored on each
patient’s risk profile (e.g., associations of diabetes mellitus
and other high-risk conditions) and might be reasonable
only in case of a notable 10-year risk of primary vascular
events (3, 4).
The possibility to test the biological effectiveness of
antiplatelet agents, with platelet function testing devices
such as Multiplate Analyzer R©, might supply helpful information
to clinicians, primarily to assess the responsiveness to ASA
or Clopidogrel in ischemic stroke patients. Nevertheless,
it might be a valid tool in the stratification of patient’s
risk profile as well, while considering the safety of a
primary prevention regimen, particularly in the presence
of clinical conditions associated with an increased risk of
hemorrhagic complications.
However, longitudinal studies are needed to assess
whether aggregometry might supply individualized
information and whether it can be considered a valid
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FIGURE 4 | Patient’s MRI at follow-up. Gradient-echo T2*-weighted sequences revealed roundish lesions underlying well-known intraparenchymal hemorrhages (A,
red arrows), with classic magnetic resonance appearance of cavernous venous malformations. (B,C) show multiple and similar lesions throughout subcortical white
matter and basal ganglia, bilaterally.
tool in the development of tailored therapies, as the
main limitation of its implementation in everyday
clinical practice.
CONCLUSION
Our report illustrates the potential clinical benefit of platelet
function testing in patients undergoing antiplatelet therapy,
with particularly useful application in the definition of
patient’s risk profile in case of primary prevention treatment
with Aspirin. However, RCTs and longitudinal studies
are needed to assess whether routine platelet function
monitoring might be considered a decision-making tool
for clinicians, both in patients with vascular diseases
subjected to secondary prevention therapy and during
the evaluation of safety profile of antiplatelet treatment
in selected patients deserving of pharmacological primary
prevention therapy.
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